The first 100 patients in the U.S. treated with OssDsign Catalyst
Uppsala, June 13, 2022. OssDsign AB (publ.) today announces that the first 100 patients in the U.S. have now been treated with the company’s innovative synthetic bone graft OssDsign Catalyst. The product was launched in the U.S. market in August, 2021, and has since then been rapidly adopted by surgeons for use in spinal fusion surgeries. The achievement marks an important milestone as OssDsign continues to grow its commercial presence.
OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue.
“We are happy to announce that we have reached yet another important milestone in our aim to establish OssDsign Catalyst as the preferred product for spinal surgeries. The high rate of adoption of OssDsign Catalyst among surgeons in the U.S. is a clear acknowledgement of our innovative product offering and imperative for our continued success,” says Morten Henneveld, CEO of OssDsign.
The market approval in the U.S is based on preclinical results that surpass other synthetic bone grafts in the most established and demanding pre-clinical model for spinal fusion – the Boden model. To collect clinical data, OssDsign is currently running PROPEL, a U.S.-based multi-center prospective spinal fusion registry. In parallel, the company is conducting the clinical trial TOP FUSION in Hungary, in which patient enrolment was completed in April 2022, with patient follow-up over 24 months under the leadership of world-leading experts in spinal surgery.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: